SCHEMBL4548685

SCHEMBL4548685

CNC(=O)c1cc(Oc2ccc3c(C(=O)Nc4ccc(C(F)(F)C(F)(F)F)cc4)cccc3c2)ccn1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.76
RET P07949 2/20 0.57
PLK4 O00444 1/20 0.57
AURKA O14965 1/20 0.57
MAPK13 O15264 1/20 0.57
JAK2 O60674 1/20 0.57
MAP4K4 O95819 1/20 0.57
ABL1 P00519 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
LYN P07948 1/20 0.57
ROS1 P08922 1/20 0.57
SRC P12931 1/20 0.57
RPS6KB1 P23443 1/20 0.57
EPHA2 P29317 1/20 0.57
TYK2 P29597 1/20 0.57
AXL P30530 1/20 0.57
FRK P42685 1/20 0.57
SYK P43405 1/20 0.57
MAPK9 P45984 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747491 0.93 KDR (0.78) KDRRETPLK4AURKAMAPK13
SCHEMBL2747688 0.90 KDR (0.80) KDRRETPLK4AURKAMAPK13
SCHEMBL2747900 0.89 KDR (0.78) KDRRETPLK4AURKAMAPK13
SCHEMBL2747925 0.88 KDR (0.82) KDRRETPLK4AURKAMAPK13
SCHEMBL2748756 0.87 KDR (0.84) KDRRETPLK4AURKAMAPK13
SCHEMBL2748623 0.87 KDR (0.84) KDRAURKALCKAURKBFGFR1
SCHEMBL2746993 0.87 KDR (0.84) KDRRETFGFR1BRAFMET
SCHEMBL2437469 0.87 KDR (0.71) KDRRETPLK4AURKAMAPK13
SCHEMBL2747600 0.86 KDR (1.00) KDRAURKALCKAURKBFGFR1
SCHEMBL2748546 0.86 KDR (0.82) KDRFGFR1RAF1BRAFMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885PLK4 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.